NovoCure NVCR Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $674.41M+2.9% | $655.35M+2.0% | $642.27M+1.9% | $630.16M+1.4% | $621.71M+2.7% | ||
| $167.29M+0.2% | $166.88M+5.5% | $158.19M+6.3% | $148.83M+4.8% | $142.01M+3.5% | ||
| $507.13M+3.8% | $488.47M+0.9% | $484.08M+0.6% | $481.33M+0.3% | $479.7M+2.5% | ||
| 75.2%+0.7pp | 74.5%-0.8pp | 75.4%-1.0pp | 76.4%-0.8pp | 77.2%-0.2pp | ||
| $229.1M+2.0% | $224.54M+4.5% | $214.85M+1.0% | $212.7M+0.4% | $211.82M+1.0% | ||
| $242.63M+1.1% | $240.06M+0.5% | $238.82M-0.5% | $240.1M+0.2% | $239.65M+0.2% | ||
| $218.75M+23.1% | $177.67M-14.2% | $207.13M+2.9% | $201.31M+3.2% | $195.07M+2.8% | ||
| $690.48M+7.5% | $642.27M-2.8% | $660.79M+1.0% | $654.11M+1.2% | $646.54M+1.3% | ||
| $690.48M+7.5% | $642.27M-2.8% | $660.79M+1.0% | $654.11M+1.2% | $646.54M+1.3% | ||
| -$183.36M-19.2% | -$153.8M+13.0% | -$176.71M-2.3% | -$172.78M-3.6% | -$166.84M+2.1% | ||
| -27.2%-3.7pp | -23.5%+4.0pp | -27.5%-0.1pp | -27.4%-0.6pp | -26.8%+1.3pp | ||
| $8.7M-51.9% | $18.11M-30.9% | $26.21M-14.7% | $30.72M-17.0% | $37.03M-5.9% | ||
| -$175.21M-28.6% | -$136.25M+9.5% | -$150.5M-5.9% | -$142.07M-9.4% | -$129.82M+1.0% | ||
| -$2.17M-9,322% | -$23K-100% | $27.15M-6.0% | $28.89M-16.0% | $34.37M-8.3% | ||
| -$173.05M-27.0% | -$136.23M+23.3% | -$177.65M-3.9% | -$170.95M-4.1% | -$164.19M+2.6% | ||
| -25.7%-4.9pp | -20.8%+6.9pp | -27.7%-0.5pp | -27.1%-0.7pp | -26.4%+1.5pp | ||
| -$1.53-25.4% | -$1.22+24.2% | -$1.61-3.2% | -$1.56-3.3% | -$1.51+3.2% | ||
| -$1.53-25.4% | -$1.22+24.2% | -$1.61-3.2% | -$1.56-3.3% | -$1.51+3.2% | ||
| 449.1M+0.9% | 445.2M+0.8% | 441.6M+0.8% | 437.9M+0.9% | 434.1M+0.7% | ||
| 449.1M+0.9% | 445.2M+0.8% | 441.6M+0.8% | 437.9M+0.9% | 434.1M+0.7% | ||
| $8.7M-51.9% | $18.11M-30.9% | $26.21M-14.7% | $30.72M-17.0% | $37.03M-5.9% | ||
| -$183.36M-19.2% | -$153.8M+13.0% | -$176.71M-2.3% | -$172.78M-3.6% | -$166.84M+2.1% | ||
| -$167.91M-20.7% | -$139.15M+14.7% | -$163.18M-1.7% | -$160.45M-3.5% | -$155.1M+2.6% | ||
| -$167.91M-20.7% | -$139.15M+14.7% | -$163.18M-1.7% | -$160.45M-3.5% | -$155.1M+2.6% | ||
| -24.9%-3.7pp | -21.2%+4.2pp | -25.4%+0.1pp | -25.5%-0.5pp | -24.9%+1.4pp | ||
| -$183.36M-19.2% | -$153.8M+13.0% | -$176.71M-2.3% | -$172.78M-3.6% | -$166.84M+2.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is NovoCure's revenue?
- NovoCure (NVCR) generated $674.4M in revenue over the trailing twelve months, up 8.5% year over year.
- Is NovoCure profitable?
- NovoCure is not currently profitable: it reported a net loss of $173.0M over the trailing twelve months, a -25.7% net margin.
- What are NovoCure's profit margins?
- Gross margin is 75.2% and operating margin is -27.2%, with a -25.7% net margin.
- What is NovoCure's earnings per share?
- NovoCure's diluted EPS over the trailing twelve months is $-1.53.
- Where does NovoCure's income statement data come from?
- Every line is extracted from NovoCure's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
